Siegfried Holding AG
SIX:SFZN

Watchlist Manager
Siegfried Holding AG Logo
Siegfried Holding AG
SIX:SFZN
Watchlist
Price: 1 114 CHF 0.91% Market Closed
Market Cap: 4.8B CHF
Have any thoughts about
Siegfried Holding AG?
Write Note

Siegfried Holding AG
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Siegfried Holding AG
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Siegfried Holding AG
SIX:SFZN
Cash from Operating Activities
CHf248.8m
CAGR 3-Years
14%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Bachem Holding AG
SIX:BANB
Cash from Operating Activities
CHf243.5m
CAGR 3-Years
28%
CAGR 5-Years
34%
CAGR 10-Years
19%
Lonza Group AG
SIX:LONN
Cash from Operating Activities
CHf1.5B
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
10%
Tecan Group AG
SIX:TECN
Cash from Operating Activities
CHf121.5m
CAGR 3-Years
-20%
CAGR 5-Years
6%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Cash from Operating Activities
€36.5m
CAGR 3-Years
-10%
CAGR 5-Years
10%
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Cash from Operating Activities
CHf8.7m
CAGR 3-Years
-27%
CAGR 5-Years
31%
CAGR 10-Years
N/A
No Stocks Found

Siegfried Holding AG
Glance View

Market Cap
4.8B CHF
Industry
Life Sciences Tools & Services

Siegfried Holding AG engages in the development and manufacture of active pharmaceutical ingredients for pharmaceutical clients with research and development programs, related intermediates, and controlled substances. The company is headquartered in Zofingen, Aargau and currently employs 3,432 full-time employees. The firm produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and steriles. The firm's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The firm operates production facilities in Switzerland, Germany, France, Malta, the United States and China.

SFZN Intrinsic Value
1 192.72 CHF
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Siegfried Holding AG's Cash from Operating Activities?
Cash from Operating Activities
248.8m CHF

Based on the financial report for Jun 30, 2024, Siegfried Holding AG's Cash from Operating Activities amounts to 248.8m CHF.

What is Siegfried Holding AG's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
17%

Over the last year, the Cash from Operating Activities growth was 72%. The average annual Cash from Operating Activities growth rates for Siegfried Holding AG have been 14% over the past three years , 17% over the past five years .

Back to Top